Fragmin (dalteparin sodium) / Pfizer, Eisai - LARVOL DELTA

Venous Thromboembolism in Lymphoma: Risk Stratification and Evolving Anticoagulation Strategies (SOHO 2026) - "In the treatment setting, rivaroxaban reduced VTE recurrence to 4% vs 11% with dalteparin, while edoxaban demonstrated a 7.9% vs 11.3% recurrence rate, and a meta-analysis of four major trials confirmed DOACs significantly reduce recurrent thrombosis compared with LMWH without significantly increasing major bleeding... Patients with lymphoma face a substantial and subtype-dependent VTE burden, concentrated in the early chemotherapy period. DOACs demonstrate superior efficacy over LMWH for treatment and show prophylactic benefit in high-risk ambulatory patients, although lymphoma-specific trial representation remains limited. Prospective lymphoma-dedicated trials are needed to establish evidence-based anticoagulation protocols."

B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

Inhibitor-Regulated Cas12a Activation Enables Highly Sensitive and One-Pot Detection of Drug-Resistant Genes in River Water. (PubMed, Anal Chem) - "To overcome compatibility challenges between RPA and CRISPR systems, four glycosaminoglycans (heparin sodium, nadroparin calcium, dalteparin sodium, and chondroitin sulfate A sodium salt) with different molecular weights or negative charge density were evaluated as Cas-enzyme activity modulators. This assay achieved high sensitivity and specificity when it was applied to river samples, matching the performance of qPCR. The developed assay is simple to operate, has high sensitivity, and is widely adaptable, providing a robust tool for rapid antimicrobial resistance surveillance and exhibiting promise for public health management applications."

Journal

Direct oral anticoagulants in cancer-associated venous thromboembolism: trial robustness and clinical trade-offs. (PubMed, Res Pract Thromb Haemost) - "Smaller trials (apixaban and dalteparin in active malignancy associated venous thromboembolism and Selected Cancer Patients at Risk of Recurrence of Venous Thromboembolism) demonstrated higher absolute efficacy (NNT, <20) but extreme fragility (FI, 0-2), whereas larger trials (Hokusai VTE Cancer, Caravaggio, and Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban) showed modest absolute benefits with slightly higher stability. DOACs are viable alternatives to low-molecular-weight heparin for cancer-associated thrombosis, but their comparative efficacy is statistically fragile and offset by bleeding risk. Considering these findings, treatment decisions require an individualized approach, weighing comorbidities and bleeding risk."

Journal • Cardiovascular • Hematological Disorders • Oncology • Oral Cancer • Respiratory Diseases • Venous Thromboembolism

In vitro comparison of the effects of abelacimab, dalteparin, and apixaban on catheter-induced clotting and thrombin generation. (PubMed, Res Pract Thromb Haemost) - "Abelacimab and dalteparin suppress catheter-induced clotting more effectively than apixaban. Clinical trials are needed to determine whether abelacimab prevents catheter-induced clotting in patients with cancer."

Clinical • Journal • Preclinical • Cardiovascular • Hematological Disorders • Oncology • Thrombosis • Venous Thromboembolism

Apixaban Versus Low-Molecular-Weight Heparin for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis. (PubMed, J Clin Med) - "Compared with dalteparin, apixaban was associated with a higher risk of clinically relevant non-major bleeding (CRNMB) (log RR 0.38; 95% CI 0.02 to 0.75), whereas, compared with enoxaparin, it was associated with a lower risk (log RR -0.49; 95% CI -0.96 to -0.02). However, given the limited number of included trials and clinical heterogeneity, the results should be interpreted cautiously. Further large-scale studies are required to confirm these observations."

Journal • Retrospective data • Review • Cardiovascular • Hematological Disorders • Oncology • Venous Thromboembolism

The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity (clinicaltrials.gov) - P3 | N=8805 | Recruiting | Sponsor: University of Calgary | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Venous Thromboembolism

Acquired haemophilia A in the setting of newly diagnosed non-metastatic gastroesophageal carcinoma – a case report (ISTH 2026) - "The patient had a history of coronary and peripheral artery disease and was on anticoagulant therapy with rivaroxaban...Ten days after rituximab administration, a single dose of 75 U/Kg of FVIII inhibitor bypassing activity (FEIBA) was delivered immediately before tumour removal via laparotomy. Early postoperative period was without excessive bleeding on the drainage sites and dalteparin prophylaxis of 5000 IU per day was maintained...One month later, warfarin was introduced by the general practitioner. Conclusions in the case of non-metastatic tumour and acquired haemophilia A, early operative management could be beneficial as a therapeutic method of resolving the underlying cause of secondary haemophilia. Table or Figure Upload (1) Laboratory parameters of oncology patient with acquired haemophilia A Page 2 DOI*10.1016/j.rpth.2026.106553"

Case report • Clinical • Metastases • Cardiovascular • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Hemophilia • Hemophilia A • Oncology • Peripheral Arterial Disease • Rare Diseases • Solid Tumor

Pharmacological thromboprophylaxis in hospitalized patients with acute infectious diseases: a meta-analysis. (PubMed, Eur J Clin Pharmacol) - "This analysis quantifies the effect of thromboprophylaxis in patients with acute infectious diseases. Although available results show that thromboprophylaxis is associated with fewer VTE events, limited data, sparse safety and mortality reporting, and heterogeneity among studies preclude reliable risk-benefit evaluation. Further prospective research is warranted."

Clinical • Journal • Retrospective data • Review • Cardiovascular • CNS Disorders • Hematological Disorders • Infectious Disease • Novel Coronavirus Disease • Pulmonary Embolism • Respiratory Diseases • Septic Shock • Venous Thromboembolism

Risky business: A retrospective cohort study of mechanical thrombectomy in high-risk acute pulmonary embolism (ISTH 2026) - "Patients were required to receive anticoagulation with heparin, enoxaparin, or dalteparin plus either alteplase or thrombectomy. Table or Figure Upload (1) Kaplan-Meier curves showing mortality after high-risk acute PE. Page 2 DOI*10.1016/j.rpth.2026.106422"

Retrospective data • Cardiovascular • Hematological Disorders • Hypotension • Immunology • Infectious Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Pulmonary Embolism • Respiratory Diseases • Septic Shock

When in doubt suck it out? A retrospective cohort study of mechanical thrombectomy in intermediate-risk acute pulmonary embolism (ISTH 2026) - "We excluded patients with hypotension, sepsis, intracardiac thrombosis, platelet count <50 x 10 9 /L, INR ≥3.0, contrast or heparin allergy, any prior CTEPH or long-term anticoagulation, or who received alteplase. Patients must have received anticoagulation with heparin, enoxaparin, or dalteparin ± thrombectomy (defined by CPT or ICD- 10 codes)...Table or Figure Upload (1) Kaplan-Meier curves showing mortality after intermediate-risk acute PE. Page 2 DOI*10.1016/j.rpth.2026.106400"

Retrospective data • Cardiovascular • Hematological Disorders • Hypotension • Immunology • Infectious Disease • Pulmonary Embolism • Respiratory Diseases • Septic Shock

During pregnancy, anticoagulant effect of low molecular weight heparin can be determined with both thrombelastography and anti-factor Xa activity, or not? (PubMed, Anaesth Intensive Care) - "Sixteen pregnant women were administered dalteparin or tinzaparin from early pregnancy until six weeks postpartum. However, the correlation between the two methods is too low to allow replacement of one by the other. Further studies are necessary to determine which of the methods best predicts anticoagulant effect and increased risk of bleeding complications related to delivery or regional anaesthesia."

Journal • Anesthesia • Cardiovascular • Venous Thromboembolism

Apixaban use in venous thromboembolism patients weighing ≤50 kg (ISTH 2026) - "Apixaban 2.5 mg group: Two patients with elevated trough levels switched anticoagulation (1 warfarin 1 dalteparin) 1 discontinued. Apixaban is an option for VTE treatment in patients weighing < 50kg. Table or Figure Upload (1) Page 2 Table or Figure Upload (2) Page 3 DOI*10.1016/j.rpth.2026.105460"

Clinical • Cardiovascular • Genetic Disorders • Musculoskeletal Diseases • Obesity • Orthopedics • Venous Thromboembolism

Bridging or No Bridging for Perioperative Management of Patients with a Mechanical Aortic Valve (ISTH 2026) - "Background The perioperative management of warfarin-treated patients with a mechanical aortic valve who need warfarin interruption for an elective surgery is uncertain, specifically as to the need for bridging, typically with a low-molecular-weight heparin (LMWH), or no bridging...Bridging was defined as administration, based on dispensed prescriptions, of ≥1 dose of a full/therapeutic-dose LMWH regimen before surgery, with either enoxaparin, dalteparin or tinzaparin...Additional, well- designed prospective studies are needed to assess the safety of a no bridging strategy in such patients. Table or Figure Upload (1) Outcomes in Bridged and Not Bridged Patients (*values of 1-5 suppressed to preserve privacy) Outcome Unweighted Weighted Bridged (n=298) Not Bridged (n=238) Bridged Not Bridged Stroke *1-5 0 0.74% 0.00% TIA *1-5 0 0.25% 0.00% Page 2 VTE *1-5 *1-5 0.69% 0.49% MI *1-5 0 0.34% 0.00% Intracranial bleed *1-5 *1-5 0.27% 0.63% Gastrointestinal bleed 2.35% *1-5 1.99%..."

Clinical • Cardiovascular

Cancer-Associated thrombosis Anticoagulation Interruption outcomes. Sub analysis of ADAM and EVE trials. (ISTH 2026) - "Aims To describe peri-procedural bleeding outcomes among patients with cancer receiving apixaban 2.5 mg, apixaban 5 mg, or dalteparin, and to characterize bleeding events within 30 days following invasive procedures. These findings highlight the heterogeneity of peri-procedural bleeding risk in CAT and support further investigation into individualized anticoagulation interruption strategies. Table or Figure Upload (1) Page 2 Table or Figure Upload (2) DOI*10.1016/j.rpth.2026.105367"

Oncology • Thrombosis

Dalteparin vs Nadroparin: A Retrospective Cohort Study of LMWH Therapy–Related Clinical Outcomes and Pain in Neonates and Young Infants (ISTH 2026) - "No clear drug-specific differences in pain were observed. DOI*10.1016/j.rpth.2026.105042"

Clinical data • Retrospective data • Cardiovascular • Hematological Disorders • Pain • Thrombosis

Apixaban Versus Dalteparin in Superficial Thrombophlebitis: a Retrospective Cohort Analysis (ISTH 2026) - "Prospective randomised controlled trials remain necessary to confirm these findings and establish definitive clinical guidelines for agent selection in STP management. DOI*10.1016/j.rpth.2026.104607"

Retrospective data • Respiratory Diseases • Varicose Veins • Venous Thromboembolism

Heparin to prevent recurrent placenta-mediated pregnancy complications in women with antiphospholipid syndrome: a systematic review. (PubMed, Res Pract Thromb Haemost) - "The FRUIT trial randomized 32 women with APS to dalteparin and aspirin or aspirin only. The trials did not report on the outcome and population as defined in the current review in a manner that allowed pooling the primary outcome. There is no high-quality evidence from RCTs that demonstrates a beneficial effect of LMWH in women with APS and placenta-mediated pregnancy complications without a history of recurrent miscarriage."

Journal • Review • Genetic Disorders • Gynecology • Hematological Disorders

ANTI-XA MEASUREMENTS IN THOSE WITH KIDNEY IMPAIRMENT IN A TERTIARY CENTRE (EHA 2026) - "Aims We report on the association of a pre-emptive dose reduction of dalteparin and its effect on anti-Xa range...Figure 1. Multivariate analysis for factors associated with bleeding and mortality"

Acute Coronary Syndrome • Cardiovascular • Chronic Kidney Disease • Hematological Disorders • Renal Disease • Thrombosis

Comparative outcomes of prophylactic anticoagulation in patients with multiple myeloma receiving immunomodulatory therapy. (ASCO 2026) - " We conducted a retrospective cohort study using the TriNetX Research Network of adults with multiple myeloma initiating IMiD therapy who received prophylactic anticoagulation with a DOAC (apixaban, rivaroxaban, edoxaban, or dabigatran) or LMWH (dalteparin or enoxaparin) within one month of diagnosis and IMiD initiation...A lenalidomide-restricted sensitivity analysis was performed... In this real-world cohort of patients with multiple myeloma receiving IMiD-based therapy, DOAC prophylaxis was associated with lower 1-year all-cause mortality compared with LMWH, with no significant differences in VTE or major bleeding. These findings support further prospective studies to define optimal thromboprophylaxis strategies in this population. Outcomes at 1 year after propensity score matching (n = 699 per cohort)."

Clinical • Immunomodulating • Cardiovascular • Hematological Malignancies • Multiple Myeloma • Venous Thromboembolism

Pulmonary Embolism & Anticoagulation Evaluation in Cancer Patient - PEACE (clinicaltrialsregister.eu) - P4 | N=234 | Not yet recruiting | Sponsor: Region Hovedstaden

New P4 trial • Cardiovascular • Oncology • Pulmonary Embolism • Respiratory Diseases

Heparin-like compounds improve the biophysical properties of eosinophilic mucus. (PubMed, Allergol Int) - "These findings suggest that heparin-like compounds interact with EET-associated histones and alter the mucus polymer network, thereby improving the biophysical properties of pathological mucus by reducing its viscosity and enhancing its hydrophilicity."

Journal • Otorhinolaryngology • Respiratory Diseases • Sinusitis

THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE) (clinicaltrials.gov) - P4 | N=3175 | Recruiting | Sponsor: Imperial College London | N=6660 ➔ 3175

Enrollment change • Cardiovascular • Varicose Veins • Venous Thromboembolism

Direct oral anticoagulants versus low-molecular-weight heparin for venous thromboembolism in primary brain tumors: A TriNetX real-world analysis. (ASCO 2026) - "Cohorts included patients treated with DOACs (apixaban, rivaroxaban, edoxaban, or dabigatran) or LMWH (enoxaparin, dalteparin, or tinzaparin) after VTE diagnosis. In this large real-world cohort of adults with primary brain malignancy and VTE, DOAC treatment was associated with a lower intracranial hemorrhage risk and reduced mortality at 180 days compared with LMWH after propensity score matching. These findings support the safety of DOACs in patients with primary brain tumors and warrant further prospective evaluation of anticoagulant selection in this high-risk population."

Clinical • Real-world • Real-world evidence • Brain Cancer • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Diabetes • Genetic Disorders • Metabolic Disorders • Nephrology • Obesity • Oncology • Renal Disease • Solid Tumor • Venous Thromboembolism

MAGNOLIA: A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE (clinicaltrials.gov) - P3 | N=417 | Completed | Sponsor: Anthos Therapeutics, Inc. | Active, not recruiting ➔ Completed

Trial completion • Cardiovascular • Genito-urinary Cancer • Oncology • Respiratory Diseases • Solid Tumor • Venous Thromboembolism

MAGNOLIA: A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE (clinicaltrials.gov) - P3 | N=417 | Terminated | Sponsor: Anthos Therapeutics, Inc. | Trial completion date: Feb 2027 ➔ Apr 2026 | Active, not recruiting ➔ Terminated | Trial primary completion date: Dec 2026 ➔ Apr 2026; Sponsor Decision

Trial completion date • Trial primary completion date • Trial termination • Cardiovascular • Genito-urinary Cancer • Oncology • Solid Tumor • Venous Thromboembolism